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Abstract
Dr. Robert C. Gallo provides a personal reflection on the 25 year history of AIDS.
Reflection
A reflection on the 25 year history of AIDS can begin with
no better outline than that provided by the late Jonathan
Mann of WHO. A slide he gave to me in the late 1980's
divides the history of AIDS into four periods: (see fig. 1).
Jonathan could not know that the period of silent spread
(part 1 of this saga) of HIV actually began years earlier. We
now know that, by 1971, the virus had moved to several
different regions of the world, but exactly when it came
out of Africa is conjectural.
There has been considerable attention (no less than three
papers in Science and Nature over the past few years from
B. Hahn and her colleagues) that the natural reservoir for
HIV-1 is a particular subspecies of chimp [1-3]. The pri-
mate-to-man origin of HIV was suspected almost from the
beginning, albeit without knowing which primate. The
reasons were three fold: 1) the early evidence that HIV was
widespread in central Africa; 2) the evidence that HIV was
more variable in Africa (hence longer presence); and 3)
prior experience with HTLV-1 and HTLV-2 and their
related retroviruses in African and Asian primates (STLV
strains), especially the evidence suggesting a chimp origin
of HTLV-1, coupled with the discovery of SIV by scientists
in Boston, and later of many other strains identified in
various African but not Asian monkeys. Human sera
reacted better with some of these SIV strains from West
Africa than they did with HIV-1, giving impetus to the
work that led to the finding of HIV-2, and the obvious
conclusion that HIV-2 came into man from these mon-
keys (sooty mangabey) [4].
But, how did the original infection of people in rainforests
become an epidemic? Here we must rely on history. I pre-
sume people in rainforests (especially hunters) were occa-
sionally infected for a long time, but died with their
disease. Migration to cities may have been associated with
increased prostitution. The movement of the rainforests
to the world can be seen as the consequence of post World
War II societal changes: increased travel with increased
promiscuity, advancing intravenous drug addiction, and
blood and blood products moving from one nation to
another for medical purposes.
Part 2 (Fig. 1) is the identification of the disease by U.S.
clinicians (1981) [5-7], and defining it as an immune dis-
order characterized by a decline of immune function and
of T cells, and notably CD4 T cells, and by 1982 the iden-
tification of risk groups then called the "4 H's" (hemo-
philiacs, heroin addicts, homosexuals and Haitians). It is
in the period (1982) when my colleagues and I began to
think about this problem, and we initiated our first exper-
iments in May 1982.
Along with Max Essex in Boston, I speculated in early
1982 that AIDS would be caused by a retrovirus. This was
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based on information that some retroviruses, like feline
leukemia virus (FeLV), caused not only leukemia, but
blood cell deficiencies including those of T cells [8]. This
was apparently associated with genetic changes in the
FeLV envelope. More importantly, I was influenced by our
experiences with human retroviruses (HTLV-1 and HTLV-
2), which we had only recently discovered [9-11]. The rea-
sons were six fold: 1) HTLV-1 and HTLV-2 mainly targeted
CD4 T cells; 2) we knew they were transmitted by blood,
sex, and mother to infant especially by breast feeding.
These were precisely the suggested modes of transmission
of the putative microbial cause of AIDS suggested by
James Curran of the U.S. Centers for Disease Control
(CDC); 3) HTLV's were endemic in parts of Africa and in
Haiti, and CDC had announced these were hot-beds for
AIDS; 4) we knew that, even in the absence of leukemia,
HTLV-1 could cause minor immune impairment; 5) we
had just discovered HTLV-1 and HTLV-2, so why not a 3rd
human retrovirus, and one with the capacity to cause a
profound immune disorder? 6) finally, as we began this
work somewhat tentatively, I was encouraged by David
Baltimore, who independently wondered aloud to me
that a retrovirus was probably the origin of AIDS.
The idea, however, has sometimes been misunderstood
and misrepresented as our hypothesizing that HTLV-1
itself was the cause of AIDS. That is clearly not the case.
Our idea was that AIDS would be caused by a new retro-
virus, but one in the HTLV family. At the time, there were
at least a dozen theories as to the cause of AIDS, including
non-infectious causes. Our hypothesis was the one that
bore fruit. As we soon learned to our astonishment, HIV
would be in a separate family of retroviruses.
J. Mann's Part 3 of AIDS history are the years 1983–85. He
called this the period of intense discovery. It begins with
the isolation of HIV. Our approach to find the virus of
AIDS was to follow our successful pattern with the
HTLV's, namely, the culture of blood cells from patients,
activation of the T cells in these samples, growth of the T
A summary of the five periods of AIDS history as modified after Jonathan Mann Figure 1
A summary of the five periods of AIDS history as modified after Jonathan Mann.
Periods of Aids History
I. Silent Spread (1970’s-1981).
II. Recognition (1981-1982).
III. Intense Discovery (1982-1985).
IV. Global Mobilization (1986-1988).
V. Ending the Problem by, Blood Testing (1984      )
Public Education (1986       )
Anti-viral Treatment (1986        )
Development of a Vaccine ( ?  ? )
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cells with IL-2, and search for reverse transcriptase actively
in the supernatant. If positive, we would look for some
cross reactivity with HTLV-1 or HTLV-2 with antibodies to
proteins of these viruses. Concomitantly, we probed DNA
and RNA of some primary tissues of AIDS patients using
cDNA from HTLV-1 under rather relaxed conditions in
order to detect sequences that might be related to HTLV-1
and 2. In 1982 and in early 1983, these experiments gave
variable results that were sometimes highly positive, other
times borderline or even negative. In retrospect, the highly
positive samples (with sequences related to HTLV) were
due to patients being doubly infected with HTLV-1 or
HTLV-2 plus HIV, which occurred in close to 10% of our
samples. Negative or borderline RT positive samples were
due to our performing the RT assays later than the optimal
peak of virus production, which occurs days earlier with
HIV than with HTLV. Luc Montagnier was stimulated in
part by our ideas brought to France by the French clinician
Jacques Leibowitch and, in early 1983, I sent Montagnier
IL-2 and antibodies against the HTLV's. He and his co-
workers had found evidence of a retrovirus in a patient
with lymphadenopathy, and they could distinguish it
from the HTLV-1 and with those antibodies [12]. This was
the first "clean" finding of HIV. Our samples at that time
always had HTLV-1 as the dominant virus. However, by
mid 1983, we were able to obtain many isolates of HIV,
and by the time we published our papers (May 4, 1984)
we described isolates from 48 patients [13]. Importantly,
we were able to put six of these isolates into continuously
growing T cell lines [14].
This was the necessary breakthrough, because for the first
time there would be sufficient virus for detailed character-
ization and the development of a workable HIV blood
test. The blood test (for serum antibodies to HIV), along
with the large number of isolates from AIDS patients, were
the major convincing results that HIV (which at the time
we called HTLV-III and the French group called LAV) was
the causative agent of AIDS [15].
Demonstrating that HIV was the cause of AIDS provided
some special challenges – unlike most viral infections.
The first was the long period between infection and the
signs of AIDS (5 to 15 years). Physicians and public health
officials do not ask a patient what they did a decade ear-
lier, but rather think in terms of days or weeks. The second
was the numerous infections a patient develops as they
present with AIDS. Which one, if any, was the cause? The
third was our concerns about verification. For rapid
progress, it was essential to have rapid verification, and
there were at least two factors that could greatly prolong
achieving this goal. (1) Samples from AIDS patients were
not only limited, but some institutions had forbade even
their entry due to fears of infection. (2) T-cell culture tech-
nology, though available in immunology laboratories,
was not widely available in virology laboratories. Both of
these restrictions made it unlikely that there would be suf-
ficiently rapid and conclusive confirmation by HIV isola-
tion. Consequently, the blood test seemed to us to be
particularly urgent for three reasons: 1) it allowed preven-
tion of HIV transmission from contaminated blood; 2) it
opened the door to our ability to follow the epidemic
from the early period of infection, and 3) it provided for
verification of HIV's causative role in AIDS. The test for
serum antibodies was simple, inexpensive, safe, rapid,
sensitive and accurate. Consequently, verification came
rapidly and globally.
A problem then occurred that enormously hindered our
work over the coming years. One of our culture samples
became contaminated with virus sent to us by Luc Mon-
tagnier. At first we stubbornly refused to believe that this
was possible, because the strain of HIV from Paris had dif-
ferent characteristics in cell culture. However, this has
now been clarified [16,17]. Montagnier had unknowingly
sent us a very different strain of HIV that grows well in cell
lines. This strain contaminated his culture of LAV before it
contaminated one of ours.
Then, from all sides and in big doses, came patent suits
over royalties to the blood test, lawyers, media, politics
and just plain pressure. Meanwhile, there were other odd
problems such as people who denied the existence of
AIDS, others who believed HIV did not exist, groups who
believed HIV existed, but didn't cause AIDS, and those
who believed HIV existed, caused AIDS, and was devel-
oped in a U.S. laboratory to kill African Americans and
gay men. Suffice it to say, no scientist is prepared for
things like this. Despite these distractions, science pro-
gressed with great speed. Mann called it the fastest pace of
discovery in medical history from the time of inception of
a new disease.
To briefly revisit that period, some of the noteworthy
advances are listed here. They include discovery of HIV
(1983–84) [12-14]; convincing evidence that it was the
cause of AIDS ('84) [15,18,19]; modes of transmission
understood ('84–'85); genome sequenced ('85) [20-22];
most genes and proteins defined ('84–'85) though not all
their functions[23-25]; main target cells CD4 T cells, mac-
rophages, and brain microglial cells – elucidated [26,27];
key reagents produced and made available for involved
scientists all over the world ('84–'85); genomic heteroge-
neity of HIV ('84) – including the innumerable microvar-
iants within a single patient ('86–'88) [28,29], first
practical life saving advance ('85); the blood test
('84)[30]; close monitoring of the epidemic for the first
time, because of the wide availability of the blood test
('85); the SIV-monkey model ('85) [31,32]; the beginningRetrovirology 2006, 3:72 http://www.retrovirology.com/content/3/1/72
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of therapy – AZT ('85)[33]; and the beginning under-
standing of pathogenesis ('85)[34].
These rapid advances led to expectations that AIDS might
be quickly solved. However, those scientists with experi-
ence in retrovirology knew differently: Unless a successful
vaccine was soon available, this would be a long road – an
infection that might be permanent in the population as
retroviruses are in many species. Furthermore, we knew by
mid-1984 that the infection was becoming global. We had
tested sera from many countries, and we could follow the
evidence for HIV coming into a region (a positive HIV
blood test) with subsequent AIDS. However, we could
never anticipate the HIV African tragedy.
Despite the rapid advances in those years, I think it is still
appropriate to ask whether we could have done better. For
example, were we as medical scientists, health officials,
doctors or simply as members of society prepared? The
answer is an interesting mix of opposites! On the one
hand, if AIDS had to come, we were lucky that (scientifi-
cally speaking) it came at a very good time. The 1970's saw
the revelation of the replication cycle of animal retrovi-
ruses (so we had a framework to work by once HIV was
established as the cause). We had most modern tools of
molecular biology (mainly developed in the 1970's). We
had monoclonal antibodies also developed in the 1970's.
We had access to technology to grow human T-cells with
IL-2 which my colleagues and I developed in the mid-
1970's, and we had found other human retroviruses in the
1980's-82 giving the first credence to their presence in
humans. However, if AIDS had to come, we could also say
it came at the worst of times. It seems that people have a
memory span not longer than 25–30 years. Here are three
examples of what I mean: First, was the surprise and lack
of preparation in 1918–1919 for the great influenza epi-
demic – forgetting lessons of the late 19th century [35].
Secondly, there was surprise and lack of preparation at the
onset of the polio epidemic in the late 1940's and early
1950's [36]. It is eerie to read accounts of that period
showing that medical science in particular and society as
a whole, were focused on chronic degenerative diseases,
believing serious infectious diseases to be "conquered".
Eerie also because, thirdly that was precisely the attitude
once again by the late 1970's evidenced by the closure of
some microbiology departments, and threats of increas-
ing reductions to CDC. The microbe would be simply the
playground of the molecular biologist. Some even felt
humans could not be infected by retroviruses.
No group was really responsible for unraveling the cause
of the new epidemic, except the CDC, but in my view the
CDC cannot and does not have expertise in every class of
microbes, let alone for all types of viruses, and indeed they
had no expertise in animal or human retroviruses. Our
group became involved only after I listened to a lecture by
the CDC's James Curran, who called for help from virolo-
gists. I have suggested that the government provide base
support for 10 or more virus centers, covering all types of
viruses among the centers. These centers would be respon-
sible for providing needed expertise to the CDC for the eti-
ological agent, diagnostics and possibly therapy and
prevention. In accordance with the kind of virus sus-
pected, the center(s) would be activated. Each center
might also be required to have close collaborations with
at least two groups from developing nations.
Though the HIV blood test was brought forward rapidly
(early 1985) to large companies that could make the test
available on an industrialized scale, I believe we could
have still done better. For instance, we could have tested
the pooled plasma used for hemophiliacs in 1984 without
a large industrial scale production of the test. I don't think
anyone was thinking of this. We were advised to return to
basic laboratory research and assumed someone would be
doing these tests. The lesson here for me is to take more
control of things that come from your own work.
Where did things go since this early period of 1982–85?
Jonathan Mann describes Part 4 ('86) as the time of global
mobilization. This means education leading to preven-
tion of infection, and no doubt this was the second major
practical advance and it continues today with results that
vary in place and even in time. There is proven success in
some places, but not all, and sometimes there is only tem-
porary success. It is noteworthy that appropriate educa-
tion also depends upon the blood test, hence on basic
science.
There were many other major advances over these next 20
years ('86-06), but none were more important than ther-
apy. This is listed as Part 5 of Mann's summary, but it was
added by me as the "period" era of practical advances, but
the time lines for these advances are actually from 1984–
1995. AZT showed for the first time that a viral disease
could be objectively treated (decline in virus levels and
lessened signs of AIDS), and there is no need to embellish
here on the great advances made with the triple drug ther-
apy in the mid 1990's. This was from contributions of a
great number of scientists: those who contributed to our
basic understanding of HIV replication, and as a result to
targets for therapy, and those who developed the culture
systems to grow HIV that could also be used in drug test-
ing, and of course to the pharmaceutical industry, espe-
cially those like E. Emini who helped design and develop
the protease inhibitors.
The other major practical advances in the last two decades
have mainly been an extension of the earlier ones: more
widespread use of the blood test as well as educationalRetrovirology 2006, 3:72 http://www.retrovirology.com/content/3/1/72
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programs; refining therapies; learning about HIV drug
resistance and how best to avoid it; better care of patients;
and learning about serious co-infections especially of
tuberculosis and HCV. A selection of the most important
basic science advances will be debatable. In my view, the
most important include the following: clarification of the
two HIV strain functional extremes – the pure CCR5
tropic viruses and the CXCR4 tropic viruses [37-42], for
review, see [43,44]; the discovery of the first endogenous
inhibitors of HIV (β-chemokines) [44]; elucidation of the
mechanisms involved in the action of some the HIV non-
structural proteins [45,46]; an appreciation of the role of
abnormal immune activation in pathogenesis, which
impacts not only HIV infected cells, but is also detrimen-
tal to uninfected immune cells for review, see [44,47];
major advances in our understanding of the various types
of HIV in different regions of the world and new recom-
binant forms; evolving knowledge of the envelope struc-
ture [48,49]; the details of HIV entry into cells [50]; and
various genetic and some environmental mechanisms for
resisting infection and slowing progression to AIDS in
infected persons, as well others fostering infection and
progression [51,52]. These latter basic advances have
already had their practical impact, including for example
several new approaches for drugs that target HIV entry.
We have reached the end of the first 25 years of AIDS, and
we can safely say that we know as much about HIV as we
do of any pathogen and about AIDS as we do any human
disease. The remaining problems and needs are evident:
bringing therapy and better health infrastructure to poor
nations; continuing to develop new treatments because of
the need for life-long therapy and the associated drug side
effects and HIV resistance; continuing and advancing edu-
cation; global monitoring of the different strains of HIV
for changes in their virulence, transmissibility and drug
resistance; and development of a preventive vaccine
which provides sterilizing immunity (or close to it) [53].
For a successful vaccine, I believe we need neutralizing
antibodies that are sustained (do not need rapid recall),
and I think this is a reachable objective. Parenthetically, it
has often been erroneously said (most recently in the New
York Times reporting of the Toronto International AIDS
Conference) that, at the April 1984 press conference, Sec-
retary of Health, Margaret Heckler stated that a successful
vaccine would be available within two years. Transcripts
of comments are still available and show that no such
claim was made. Rather, it was said that the virus could be
continuously produced in large amounts, thereby making
trials possible within two years. Indeed, this proved true,
because in 1986, Daniel Zagury carried out some phase 1
trials in Africa and in Paris.
Several encouraging developments provide some opti-
mism for the future, such as the ability of some nations to
diminish rates of infection by education, and major new
funding sources aimed at practical achievements. One
laudable example is President Bush's Emergency Plan for
AIDS Relief, which is providing $15 billion for therapy for
HIV positive patients in needy nations. We have been
impressed that this effort carries out its mission with lead-
ership by university clinical scientists who work with
groups with long experience in the specific country. In
contrast to alternative plans that simply and rapidly pro-
vide funds for the drugs, these programs add to local infra-
structure and training, thereby reducing the prospects for
creating more multi-drug resistant HIV mutants. Private
foundations have also been a new forceful addition; Inter-
national AIDS Vaccine Initiative (IAVI) for developing
vaccine candidates and the Bill and Melinda Gates Foun-
dation for fulfilling many needs.
There are also major concerns for the future. We know sci-
ence is essential for solving the HIV problem and, as noted
before, science has been responsible for all the major prac-
tical advances in fighting this disease. However, there is a
growing distance between scientists and the larger public.
John Moore of Cornell Weill Medical School reminded
me that C.P. Snow wrote about this in the 1950's, but I
think the gap has continued to widen as technology
becomes more and more specialized. Sometimes, it leads
to tension and even hostility by the larger public toward
scientists. This is sometimes evident in AIDS, seemingly so
in recent years. Consider a recent CNN program that was
a positive educational force, but advertised as one com-
posed of AIDS experts. However, not one scientist was
among the experts, and the program ended with a movie
actor stating that to solve the problem, we all "had to be
together." It was togetherness rather than science that he
informed us would solve AIDS.
To return to and end on a positive note: it is interesting
and useful to remember that there has been some silver
lining on the dark AIDS clouds. Consider the many posi-
tive spin-offs to science in immunology, cancer biology,
basic virology, and even molecular biology along with the
leadership and focus AIDS research has provided to ther-
apy of viral infections and to vaccine development. Posi-
tive spin-offs have not been limited to science. Consider
how AIDS has inspired far greater tolerance (at least in the
West) of differences in sexuality and much greater scien-
tific and humanitarian collaborations between developed
and less developed nations. Certainly, this is the case for
relations between the U.S. and Africa. Let us hope these
advances in understanding and in conscience will con-
tinue to evolve and grow so that there will be no need for
anyone to reflect on AIDS in its 50th birthday year.Retrovirology 2006, 3:72 http://www.retrovirology.com/content/3/1/72
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